pharma · Generalized Myasthenia Gravis · Chronic inflammatory demyelinating polyneuropathy (CIDP)
Argenx
argenx
argenx is a pharma organization headquartered in GENT, BE. Primary therapeutic focus areas include Generalized Myasthenia Gravis, Chronic inflammatory demyelinating polyneuropathy (CIDP), Bullous Pemphigoid, Thyroid Eye
33 Arch Street, Suite 3201, Boston, MA 02110, US HQ
2008 Founded
2,179 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 33 Arch Street, Suite 3201, Boston, MA 02110, US
- Founded
- 2008
- Employees
- 2,179
- Programs
- 32
- Drugs
- 16
- Patents
- 0
A study to assess the safety of ARGX-121 in Healthy Adult Participants
Phase 1 · other · Healthy volunteers
A study to assess the safety of ARGX-121 in Healthy Adult Participants for Healthy volunteers is a Phase 1 program (other) at argenx with 1 ClinicalTrials.gov record(s).
Internal code ARGX-121-2401
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- argenx
- Phase
- Phase 1
- Modality
- other
- Indication
- Healthy volunteers
- Status
- active
- Trials
- 1